Tags

Type your tag names separated by a space and hit enter

Cost effectiveness of influenza vaccination in patients with acute coronary syndrome in Korea.
Vaccine. 2017 05 15; 35(21):2811-2817.V

Abstract

BACKGROUND

Influenza can cause cardiovascular abnormalities by inappropriately activating the coagulation cascade. Therefore, influenza vaccination is important because it decreases the risk of hospitalization for and mortality associated with heart disease. In particular, it reduces the occurrence of major adverse cardiovascular events (MACEs) in acute coronary syndrome (ACS) patients. Our study aimed to estimate the disease burden of MACEs and its related direct and indirect costs in ACS patients.

METHODS

We estimated the direct and indirect cost of MACEs in ACS patients using a probabilistic model and the Health Insurance Review and Assessment (HIRA)-National Patient Sample (NPS) database. The effect of the influenza vaccination on the rate of MACE in ACS patients was determined using a previous systematic review and meta-analysis.

RESULTS

Our study included 682,258 ACS patients obtained from the 2013 NPS database. According to our model, influenza vaccination would prevent 16,514 MACE-related hospitalizations and 2764 premature deaths in Korea per year. The overall reduction in costs would be $86.2 million per year from a societal perspective. Based on the results of sensitivity analysis, most of the estimated values were in the dominant area.

CONCLUSIONS

Our findings show that influenza vaccination in ACS patients is highly cost effective in terms of lowering the cost of hospitalization and premature death due to MACE. Therefore, influenza vaccination is recommended as a means of relieving the clinical and socioeconomic burdens associated with ACS.

Authors+Show Affiliations

Division of Licensing of Medicines and Regulatory Science, The Graduate School Pharmaceutical Management, Chung-Ang University, Seoul 06974, South Korea. Electronic address: danjin136@gmail.com.Evidence-Based Research and Clinical Research Lab., Department of Health, Social and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul 06974, South Korea. Electronic address: boyeon022@hanmail.net.Division of Licensing of Medicines and Regulatory Science, The Graduate School Pharmaceutical Management, Chung-Ang University, Seoul 06974, South Korea. Electronic address: yunseok.yang@hanmi.co.kr.The Graduate School Pharmaceutical Management, Chung-Ang University, Seoul 06974, South Korea; Pharmaceutical Management, Economics, and Policy Lab., College of Pharmacy, Chung-Ang University, Seoul 06974, South Korea. Electronic address: dongsuh75@gmail.com.Division of Licensing of Medicines and Regulatory Science, The Graduate School Pharmaceutical Management, Chung-Ang University, Seoul 06974, South Korea; Evidence-Based Research and Clinical Research Lab., Department of Health, Social and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul 06974, South Korea; The Graduate School Pharmaceutical Management, Chung-Ang University, Seoul 06974, South Korea. Electronic address: eykimjcb777@cau.ac.kr.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

28427844

Citation

Suh, Jinuk, et al. "Cost Effectiveness of Influenza Vaccination in Patients With Acute Coronary Syndrome in Korea." Vaccine, vol. 35, no. 21, 2017, pp. 2811-2817.
Suh J, Kim B, Yang Y, et al. Cost effectiveness of influenza vaccination in patients with acute coronary syndrome in Korea. Vaccine. 2017;35(21):2811-2817.
Suh, J., Kim, B., Yang, Y., Suh, D. C., & Kim, E. (2017). Cost effectiveness of influenza vaccination in patients with acute coronary syndrome in Korea. Vaccine, 35(21), 2811-2817. https://doi.org/10.1016/j.vaccine.2017.04.016
Suh J, et al. Cost Effectiveness of Influenza Vaccination in Patients With Acute Coronary Syndrome in Korea. Vaccine. 2017 05 15;35(21):2811-2817. PubMed PMID: 28427844.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost effectiveness of influenza vaccination in patients with acute coronary syndrome in Korea. AU - Suh,Jinuk, AU - Kim,Boyeon, AU - Yang,Yunseok, AU - Suh,Dong-Churl, AU - Kim,Eunyoung, Y1 - 2017/04/17/ PY - 2016/11/09/received PY - 2017/04/06/revised PY - 2017/04/07/accepted PY - 2017/4/22/pubmed PY - 2018/1/9/medline PY - 2017/4/22/entrez KW - Acute coronary syndrome KW - Cost effectiveness KW - Influenza vaccination KW - Korea SP - 2811 EP - 2817 JF - Vaccine JO - Vaccine VL - 35 IS - 21 N2 - BACKGROUND: Influenza can cause cardiovascular abnormalities by inappropriately activating the coagulation cascade. Therefore, influenza vaccination is important because it decreases the risk of hospitalization for and mortality associated with heart disease. In particular, it reduces the occurrence of major adverse cardiovascular events (MACEs) in acute coronary syndrome (ACS) patients. Our study aimed to estimate the disease burden of MACEs and its related direct and indirect costs in ACS patients. METHODS: We estimated the direct and indirect cost of MACEs in ACS patients using a probabilistic model and the Health Insurance Review and Assessment (HIRA)-National Patient Sample (NPS) database. The effect of the influenza vaccination on the rate of MACE in ACS patients was determined using a previous systematic review and meta-analysis. RESULTS: Our study included 682,258 ACS patients obtained from the 2013 NPS database. According to our model, influenza vaccination would prevent 16,514 MACE-related hospitalizations and 2764 premature deaths in Korea per year. The overall reduction in costs would be $86.2 million per year from a societal perspective. Based on the results of sensitivity analysis, most of the estimated values were in the dominant area. CONCLUSIONS: Our findings show that influenza vaccination in ACS patients is highly cost effective in terms of lowering the cost of hospitalization and premature death due to MACE. Therefore, influenza vaccination is recommended as a means of relieving the clinical and socioeconomic burdens associated with ACS. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/28427844/Cost_effectiveness_of_influenza_vaccination_in_patients_with_acute_coronary_syndrome_in_Korea_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(17)30480-2 DB - PRIME DP - Unbound Medicine ER -